Enzastaurin

Drug Profile

Enzastaurin

Alternative Names: DB 102; Enzastaurin hydrochloride; LY-317615

Latest Information Update: 14 Dec 2016

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Antineoplastics; Indoles; Piperidines; Pyridines; Pyrrolidinones; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Protein kinase C beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma; Glioblastoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Brain cancer; Breast cancer; Cancer; Colorectal cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Glioblastoma; Lung cancer; Lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Renal cancer; Solid tumours; Waldenstrom's macroglobulinaemia

Most Recent Events

  • 01 Mar 2016 Eli Lilly completes a phase II trial in Glioblastoma (Newly diagnosed; First line therapy) in Germany (PO) (NCT00509821)
  • 17 Dec 2014 Eli Lilly and Company completes a phase II trial in Follicular Lymphoma in USA and Germany (EudraCT 2007-006246-17)
  • 16 Sep 2014 Denovo Biopharma acquires Enzastaurin from Eli Lilly
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top